NO20081941L - Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister - Google Patents

Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister

Info

Publication number
NO20081941L
NO20081941L NO20081941A NO20081941A NO20081941L NO 20081941 L NO20081941 L NO 20081941L NO 20081941 A NO20081941 A NO 20081941A NO 20081941 A NO20081941 A NO 20081941A NO 20081941 L NO20081941 L NO 20081941L
Authority
NO
Norway
Prior art keywords
corticotropin
crf
pyrazole
alpha
receptor antagonists
Prior art date
Application number
NO20081941A
Other languages
English (en)
Inventor
Frank Hossner
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081941(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20081941L publication Critical patent/NO20081941L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er generelt beskrevet polymorf form II av [3-(4-metoksy-2-metyl-fenyl)-2,5-dimetyl-pyrazolo[l,5-a]pyrimidin-7-yl]-[(S)-l-(3-metyl-[l,2,4]oksadiazol-5-yl)propyl]-amin. Det er videre beskrevet farmasøytiske preparater omfattende denne og fremgangsmåte for anvendelse derav.
NO20081941A 2005-09-30 2008-04-23 Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister NO20081941L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0519957.5A GB0519957D0 (en) 2005-09-30 2005-09-30 Chemical compound
PCT/US2005/037576 WO2006044958A1 (en) 2004-10-19 2005-10-19 Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists
PCT/EP2006/009531 WO2007039264A1 (en) 2005-09-30 2006-09-28 Pyrazolo [1, 5 -alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists

Publications (1)

Publication Number Publication Date
NO20081941L true NO20081941L (no) 2008-04-23

Family

ID=35395069

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20072541A NO20072541L (no) 2004-10-19 2007-05-16 Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster
NO20081941A NO20081941L (no) 2005-09-30 2008-04-23 Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20072541A NO20072541L (no) 2004-10-19 2007-05-16 Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster

Country Status (21)

Country Link
US (1) US7879862B2 (no)
EP (2) EP1802627B1 (no)
JP (2) JP4901744B2 (no)
KR (2) KR20070088621A (no)
CN (1) CN101273043B (no)
AR (2) AR051461A1 (no)
AU (2) AU2005295353B2 (no)
BR (1) BRPI0616767A2 (no)
CA (2) CA2584567C (no)
CR (1) CR9918A (no)
EA (1) EA200801000A1 (no)
GB (1) GB0519957D0 (no)
IL (1) IL190225A0 (no)
MA (1) MA29850B1 (no)
NO (2) NO20072541L (no)
NZ (1) NZ554082A (no)
PE (2) PE20060586A1 (no)
RU (1) RU2007118683A (no)
TW (2) TW200626599A (no)
UA (1) UA92756C2 (no)
WO (2) WO2006044958A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
RU2394035C2 (ru) * 2003-12-22 2010-07-10 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Антагонисты crf-рецепторов и способы, относящиеся к ним
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101932583A (zh) 2007-12-19 2010-12-29 沃泰克斯药物股份有限公司 用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类
CN102007133B (zh) * 2008-04-15 2013-06-12 卫材R&D管理有限公司 3-苯基吡唑并[5,1-b]噻唑化合物
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2487177A1 (en) * 2009-10-08 2012-08-15 Eisai R&D Management Co., Ltd. Pyrazoloxazole compound
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
US8835444B2 (en) * 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
US20140309226A1 (en) 2011-11-16 2014-10-16 Array Biopharma Inc. Piperidinyl-substituted cyclic ureas as gpr119 modulators
WO2013160317A2 (en) * 2012-04-23 2013-10-31 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
JP6585625B2 (ja) 2014-01-21 2019-10-02 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
CN106061975B (zh) * 2014-01-22 2019-09-24 库洛维公司 作为抗病毒化合物的吡唑并[1,5-a]嘧啶
BR112019016775A2 (pt) 2017-02-17 2020-03-31 Trevena, Inc. Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
IL294052A (en) 2019-12-20 2022-08-01 Tenaya Therapeutics Inc Fluoroalkyl-oxadiazoles and their uses
CN116406268A (zh) * 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
CN1046730C (zh) 1994-06-21 1999-11-24 株式会社大塚制药工场 吡唑并[1,5-a]嘧啶衍生物
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
PL191271B1 (pl) 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
EE04316B1 (et) * 1996-07-24 2004-06-15 Dupont Pharmaceuticals Company Asolotriasiinid ja -pürimidiinid, neid sisaldavadfarmatseutilised kompositsioonid ning nende kasutamine ravimite valmistamiseks
DE69738197T2 (de) 1996-07-24 2008-07-17 Bristol-Myers Squibb Pharma Co. Azolotriazine und pyrimidine
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
WO1999038868A1 (en) * 1998-01-28 1999-08-05 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
AU2321000A (en) 1999-01-29 2000-08-18 Sumitomo Chemical Company, Limited Fat accumulation inhibitory agents
WO2000059908A2 (en) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
WO2001023387A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
AU7737900A (en) 1999-09-30 2001-04-30 Neurogen Corporation Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
CA2446514A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
EP1395591B1 (en) 2001-06-12 2008-06-04 Glaxo Group Limited Corticotropin releasing factor antagonists
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
JP2006515334A (ja) 2003-01-16 2006-05-25 エスビー ファームコ プエルト リコ インコーポレーテッド ＣＲＦ受容体アンタゴニストとしてのヘテロアリール置換ピロロ［２，３−ｂ］ピリジン誘導体
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
JP2007515474A (ja) 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
RU2394035C2 (ru) 2003-12-22 2010-07-10 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Антагонисты crf-рецепторов и способы, относящиеся к ним
DE102004008807A1 (de) 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
ES2326827T3 (es) 2004-10-19 2009-10-20 Smithkline Beecham (Cork) Limited Anatagonistas del receptor de crf y metodos relacionados.
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
IL190225A0 (en) 2009-09-22
EP1802627B1 (en) 2012-08-29
KR20070088621A (ko) 2007-08-29
AU2005295353B2 (en) 2012-01-12
RU2007118683A (ru) 2008-11-27
PE20060586A1 (es) 2006-09-20
NZ554082A (en) 2010-12-24
JP4901744B2 (ja) 2012-03-21
CA2584567C (en) 2013-04-30
JP2009510004A (ja) 2009-03-12
EP1934222B1 (en) 2012-07-25
EP1934222A1 (en) 2008-06-25
JP2008517067A (ja) 2008-05-22
CA2624699A1 (en) 2007-04-12
CR9918A (es) 2009-02-03
AR056104A1 (es) 2007-09-19
US7879862B2 (en) 2011-02-01
AU2005295353A1 (en) 2006-04-27
TW200626599A (en) 2006-08-01
KR20080063760A (ko) 2008-07-07
MA29850B1 (fr) 2008-10-03
WO2006044958A1 (en) 2006-04-27
TW200745121A (en) 2007-12-16
BRPI0616767A2 (pt) 2011-06-28
UA92756C2 (ru) 2010-12-10
AU2006298995B2 (en) 2012-06-14
WO2007039264A1 (en) 2007-04-12
US20080194589A1 (en) 2008-08-14
PE20070845A1 (es) 2007-08-25
CN101273043B (zh) 2011-08-03
WO2006044958A8 (en) 2006-06-08
CA2584567A1 (en) 2006-04-27
GB0519957D0 (en) 2005-11-09
AR051461A1 (es) 2007-01-17
EA200801000A1 (ru) 2009-02-27
CN101273043A (zh) 2008-09-24
NO20072541L (no) 2007-06-25
AU2006298995A1 (en) 2007-04-12
EP1802627A1 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
NO20081941L (no) Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister
CO5560547A2 (es) Metodos para la preparacion de compuestos de pirrolotriazina utiles como inhibidores de cinasa
NO20075142L (no) krystallformer av asenapinmaleat
NO20072795L (no) Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
HRP20041188A2 (en) N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NZ590922A (en) Piperidine derivatives as jak3 inhibitors
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
WO2005118540A3 (en) Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
CY1107301T1 (el) Ιμιδαζο και θειαζολοπυριδινες ως αναστολεις κινασης jak3
BRPI0507005A (pt) compostos, composições farmacêuticas, uso de um composto, e, método de preparo de uma composição farmacêutica
MY152283A (en) Polo-like kinase inhibitirs
WO2009093210A3 (ru) ЗАМЕЩЕННЫЕ ЦИKЛOAЛKAHO[e ИЛИ d]ПИPAЗOЛO[l,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
PE20081377A1 (es) Compuestos de tiazol pirazolopirimidina
NO20080563L (no) Pyrazol[3,4-d]azepinderivater som histamin H3 antagonister
WO2007000340A8 (en) Bicyclic derivatives as p38 kinase inhibitors
TW200626600A (en) Octahydropyrrolo[3, 4-c]pyrrole derivatives
ATE359782T1 (de) Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren
WO2007000337A8 (en) Bicyclic derivatives as p38 kinase inhibitors
WO2003076426A3 (en) Pyridinyloxy derivatives as 5-ht receptor ligands
WO2007077574A3 (en) SULFOXIMINE DERIVATIVES AS p38 MAP KINASE INHIBITORS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application